Intuitive Surgical (NASDAQ:ISRG) Given New $410.00 Price Target at Evercore ISI

Intuitive Surgical (NASDAQ:ISRG) had its target price lowered by Evercore ISI from $425.00 to $410.00 in a report published on Friday, Benzinga reports. The firm currently has an in-line rating on the medical equipment provider’s stock.

Several other research analysts also recently weighed in on ISRG. The Goldman Sachs Group initiated coverage on shares of Intuitive Surgical in a report on Thursday, May 30th. They set a buy rating and a $500.00 price target for the company. Truist Financial increased their target price on Intuitive Surgical from $450.00 to $515.00 and gave the company a buy rating in a research note on Tuesday, July 16th. Morgan Stanley upped their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an equal weight rating in a research note on Monday, July 15th. Jefferies Financial Group upped their price target on Intuitive Surgical from $365.00 to $375.00 and gave the company a hold rating in a research report on Friday, April 19th. Finally, Stifel Nicolaus lifted their target price on Intuitive Surgical from $420.00 to $430.00 and gave the company a buy rating in a research note on Monday, April 8th. Six investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, Intuitive Surgical currently has an average rating of Moderate Buy and an average price target of $438.74.

Intuitive Surgical Price Performance

Shares of ISRG opened at $455.01 on Friday. Intuitive Surgical has a 12 month low of $254.85 and a 12 month high of $456.81. The stock’s 50-day moving average is $422.05 and its two-hundred day moving average is $394.72. The stock has a market cap of $161.39 billion, a PE ratio of 82.13, a P/E/G ratio of 5.87 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a return on equity of 13.40% and a net margin of 27.65%. Intuitive Surgical’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.18 EPS. On average, research analysts anticipate that Intuitive Surgical will post 4.8 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Robert Desantis sold 1,498 shares of the company’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $369.92, for a total transaction of $554,140.16. Following the completion of the sale, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at $2,037,149.44. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, EVP Robert Desantis sold 1,498 shares of Intuitive Surgical stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $369.92, for a total value of $554,140.16. Following the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Myriam Curet sold 5,318 shares of the company’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the sale, the executive vice president now directly owns 298 shares of the company’s stock, valued at $110,456.68. The disclosure for this sale can be found here. Insiders have sold 17,956 shares of company stock worth $6,927,011 in the last three months. 0.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Intuitive Surgical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Citizens Bank & Trust Co. boosted its position in shares of Intuitive Surgical by 4.4% in the second quarter. First Citizens Bank & Trust Co. now owns 16,544 shares of the medical equipment provider’s stock worth $7,360,000 after buying an additional 704 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Intuitive Surgical by 8.5% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 6,944 shares of the medical equipment provider’s stock valued at $3,089,000 after acquiring an additional 544 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in shares of Intuitive Surgical by 2.2% in the 2nd quarter. First Horizon Advisors Inc. now owns 6,389 shares of the medical equipment provider’s stock valued at $2,842,000 after purchasing an additional 140 shares during the period. Continuum Advisory LLC lifted its position in shares of Intuitive Surgical by 14.7% in the second quarter. Continuum Advisory LLC now owns 375 shares of the medical equipment provider’s stock worth $167,000 after purchasing an additional 48 shares in the last quarter. Finally, Apollon Wealth Management LLC boosted its holdings in shares of Intuitive Surgical by 3.2% during the second quarter. Apollon Wealth Management LLC now owns 10,308 shares of the medical equipment provider’s stock worth $4,586,000 after purchasing an additional 315 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.